More young people are being diagnosed with depression than ever before. SparkRx is a treatment option with room for all of them.
Available now, under the FDA’s Enforcement Policy during the COVID-19 public health emergency.
Limbix’s prescription digital therapeutics (PDTs) enable providers to offer evidence-based, therapeutic interventions for adolescent mental health.
PDTs require strict compliance with FDA quality management standards and are validated through rigorous clinical trials. Upon FDA clearance, PDTs can be prescribed by a doctor to treat specific medical conditions.
Limbix relies on clinical experts who provide critical product feedback to help ensure the digital therapeutics we create are evidence-based and beneficial for patients. If you are a physician looking to connect with Limbix to provide your input, please join our Physician Advisory Group.Join Physician Advisory Group